MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Cash and cashequivalents$797,798K (33.21%↑ Y/Y)Prepaid expenses andother current assets$52,683K (3.47%↑ Y/Y)Accounts receivable$697K (-64.00%↓ Y/Y)Total current assets$851,178K (30.60%↑ Y/Y)Other assets$961K (-89.25%↓ Y/Y)Property and equipment,net$351K (-52.37%↓ Y/Y)Total assets$852,490K (28.88%↑ Y/Y)Total liabilities andstockholders equity$852,490K (28.88%↑ Y/Y)Total stockholdersequity$735,388K (20.84%↑ Y/Y)Total liabilities$117,102K (121.36%↑ Y/Y)Accumulated deficit-$1,898,353K (-39.57%↓ Y/Y)Additional paid-in capital$2,632,996K (33.86%↑ Y/Y)Total currentliabilities$117,102K (121.36%↑ Y/Y)Accumulated othercomprehensive income$725K (-58.26%↓ Y/Y)Common stock, par value0.0001 per share,...$20K (25.00%↑ Y/Y)Accrued expenses andother current...$106,964K (137.40%↑ Y/Y)Accounts payable$10,138K (29.26%↑ Y/Y)
Balance Sheet
IMVT_BIG-svg

Immunovant, Inc. (IMVT)

IMVT_BIG-svg
source: myfinsight.com

Immunovant, Inc. (IMVT)